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Introduction {#sec1}
============

Toxin-antitoxin (TA) systems are widespread in prokaryotes and play a central role in the response and adaptation of bacteria to various stress conditions, including starvation, phage attack, or antibiotic treatment ([@bib22], [@bib24], [@bib37], [@bib43]). TA systems encode a toxic protein, which targets an essential physiological process in the bacterial cell, together with a toxin-neutralizing "antidote" or antitoxin. Under favorable growth conditions, toxin activity is blocked by the presence of the antitoxin. When faced with antibiotic or environmental stress, the antitoxin is rapidly degraded, which allows the toxin to become activated, thereby reducing the bacterial growth rate ([@bib10], [@bib22]). TA systems are classified in four families (I**--**IV) based on the nature of the antitoxin and the associated mechanism of toxin inhibition ([@bib24]). Most studies have focused on type II TA systems, which are composed of a protein antitoxin and toxin pair. Strikingly, type II TA systems are highly abundant in the tuberculosis (TB) bacillus, *Mycobacterium tuberculosis* (Mtb), in which they are thought to contribute to pathogenicity and persistence ([@bib31], [@bib50], [@bib53], [@bib59]). Among the ∼80 TA system-encoding operons identified in the Mtb genome, three antitoxin-encoding genes are essential for viability, as evidenced by saturating transposon mutagenesis studies ([@bib9]). This suggests that the cognate toxins of these essential antitoxins are lethal to Mtb, and such TA systems could be exploited for the development of novel anti-TB therapies.

Here, we focus on the Mtb type II TA module Rv1989c-Rv1990c, in which the antitoxin-encoding gene (Rv1990c) is essential, whereas the cognate toxin-encoding gene (Rv1989c) is dispensable for bacterial growth ([@bib9]) ([Figure S1](#mmc1){ref-type="supplementary-material"}A). This TA pair was previously identified by *in silico* genomic analysis of prokaryotic TA loci and classified as a so-called COG5654-COG5642 TA system ([@bib38]). It was predicted to encode a RES domain-containing toxin and a cognate antitoxin with a XRE-like HTH domain, typically found in phage repressor proteins ([@bib77]) ([Figure S1](#mmc1){ref-type="supplementary-material"}A). According to a SMART search for analysis of protein domain architectures, the three conserved polar groups (R-E-S) that are predicted to form an active site in Rv1989c are Arg47, Glu69, and Ser126 ([@bib35]). COG5654 or RES domains are widely spread in bacteria and often found in conjunction with various other conserved domains. Interestingly, a plasmid-encoded RES-Xre locus from the legume symbiont *Sinorhizobium meliloti* was reported to function as an active TA system ([@bib40]). The Rv1989c-Rv1990c TA system is particularly interesting because it is significantly upregulated in a variety of stress conditions, including in Mtb persister cells ([@bib31]), during hypoxic stress ([@bib52]), under starvation ([@bib21]), and within host macrophages ([@bib26]). A BLASTp search predicts Rv1989c-Rv1990c-like TA systems in multiple mycobacterial species of the *M. tuberculosis* complex ([@bib66]), with orthologs detected in a limited number of strains of opportunistic non-tuberculous mycobacteria (e.g., *M. avium*). Homologs of this TA system are also present in environmental prokaryotes, such as *Gordonia* spp ([Figure S1](#mmc1){ref-type="supplementary-material"}B). This is in line with our previous suggestion that the Rv1989c-Rv1990c TA pair was most likely acquired through horizontal gene transfer with environmental bacteria ([@bib3]). To uncover the mechanism of action of the Rv1989c toxin, we used a combination of biochemical, structural biology, and microbiological methods. We show that Rv1989c encodes a novel NAD^+^ phosphorylase, an enzymatic activity that has never been described thus far, and reveal a synergistic protective effect of toxin activity and antibiotic treatment in a mouse model of Mtb infection.

Results and Discussion {#sec2}
======================

We first expressed Rv1989c and Rv1990c from different inducible promoters in *Escherichia coli*. Induction of Rv1989c inhibited *E. coli* growth on agar plates, unless Rv1990c was co-expressed ([Figure S2](#mmc1){ref-type="supplementary-material"}A). In contrast, wild-type (WT) Mtb expressing Rv1989c from a tetracycline-inducible promoter on an integrated plasmid ([@bib13]) did not show impaired growth ([Figures 1](#fig1){ref-type="fig"}A and 1B). We hypothesized that the quantity of antitoxin protein expressed from the chromosomally encoded Rv1990c gene was sufficient to neutralize the amount of toxin expressed from both the chromosomal Rv1989c gene and the plasmid-encoded copy of Rv1989c. To test our hypothesis, we constructed a Mtb knockout (KO) mutant with a deletion of the entire Rv1989c-Rv1990c operon (Mtb^ΔTA^) by homologous recombination, as outlined in [Figures S2](#mmc1){ref-type="supplementary-material"}B--S2E. Indeed, induction of an ectopic copy of the toxin gene in the Mtb^ΔTA^ strain completely abolished mycobacterial growth, both on agar medium and in liquid culture ([Figures 1](#fig1){ref-type="fig"}A and 1B). Further, Mtb^ΔTA^ displayed a substantial decrease in colony-forming units (CFUs) after induction of the toxin gene, with a loss of more than 3-Log~10~ in CFUs over only 4 days, suggesting bactericidal activity of the toxin ([Figure 1](#fig1){ref-type="fig"}C). We then tested the viability of Mtb^ΔTA^ cells following ATc-induced expression of Rv1989c by flow cytometry analysis ([Figures 1](#fig1){ref-type="fig"}D and 1E) and fluorescence microscopy ([Figure 1](#fig1){ref-type="fig"}F) of bacteria labeled with LIVE/DEAD *Bac*Light stains. Addition of ATc to a culture of Mtb^ΔTA^ carrying an empty vector had no effect on the proportion of cells permeable to propidium iodine (PI). In contrast, for Mtb^ΔTA^ cells expressing Rv1989c, the proportion of PI-permeable cells increased from 15% in the absence ATc to 57% in the presence of ATc after 4 days incubation, indicative of the bactericidal activity of Rv1989c. To assess the expression level of the Rv1989c gene in our experimental setup, we compared Rv1989c mRNA levels in WT Mtb versus in the Rv1989c-inducible Mtb^ΔTA^ strain by real-time qPCR ([Figure S2](#mmc1){ref-type="supplementary-material"}F). Rv1989c mRNA level in the Rv1989c-induced Mtb^ΔTA^ strain was ≈2-fold higher than that in WT Mtb during exponential growth, and ≈2-fold lower than that in Mtb grown under starvation, a natural stress condition known to induce the TA system ([@bib21]). Thus, the absence of toxicity in an Mtb WT strain and the real-time qPCR analysis shows that in our experimental setup the Mtb cell death we observed by CFU counting and viability analysis in combination with flow cytometry is not due to an overwhelming production of the toxin. Taken together, these results establish that Rv1989c-Rv1990c can function as a bactericidal TA system in Mtb. Hence, we named the Rv1989c-Rv1990c system mycobacterial cidal toxin (MbcT) and antitoxin (MbcA).Figure 1Rv1989c-Rv1990c Is a Bactericidal TA System in Mtb(A) WT Mtb or Mtb^ΔTA^ transformed with pGMC derivatives carrying Rv1990c, Rv1989c, or Rv1989c-Rv1990c as indicated were grown in 7H9 ADC Tween medium. Growth on solid medium was tested by spotting serial 10-fold dilutions on 7H11 OADC agar (−ATc) or the same medium supplemented with anhydrotetracycline (+ATc) to induce transcription from the P1 promoter. Plates were observed after 20 days at 37°C. Shown data are representative of three independent experiments.(B) Growth of WT Mtb or Mtb^ΔTA^ transformed with pGMC derivatives carrying Rv1990c, Rv1989c, or Rv1989c-Rv1990c in liquid medium as monitored by turbidity measurements (McFarland units). ATc was added at day 0 to induce ectopic gene expression when indicated. Data are represented as mean of three technical replicates ± SD. Shown data are representative of three independent experiments.(C) Survival of Mtb^ΔTA^ strains carrying pGMC-TetR-P1-Rv1989c as measured by CFU scoring of liquid cultures. ATc was added at time 0 to induce expression of Rv1989c. Samples were collected at the seven different time points, cells were washed with growth medium to remove ATc and 10-fold serial dilutions were spotted on agar plates for CFU counting. Data are represented as mean of three independent replicates ± SD.(D) Mtb^ΔTA^ strains carrying pGMC-TetR-P1-Rv1989c or an empty vector control were grown for 4 days in the presence of ATc (+ATc) or left untreated (−ATc). Cells were labeled with the LIVE/DEAD *Bac*Light stains (Syto 9; propidium iodide (PI)) and analyzed by fluorescence-activated cell sorting (FACS). The empty vector control was either left unlabeled (negative control) or heat killed by incubation for 1 h at 100°C (positive control). Quadrants were established using the negative (no stain) and positive (heat-killed Mtb) controls as references. Shown data are representative of two independent experiments.(E) Bar diagram showing the fraction of Mtb^ΔTA^ cells permeable to PI and Sypro 9 as determined by FACS analysis (see D). Data are represented as mean of two independent replicates ± SD.(F) Visualization of Syto9 (green) or PI (red) incorporation in Mtb^ΔTA^ cells following ATc-induced expression of Rv1989c from pGMC-TetR-P1-Rv1989c by spinning disk confocal microscopy (see D). Mtb^ΔTA^ cells transformed with empty vector were included as a negative control. PI incorporation is indicative of membrane damage. Representative maximum intensity Z projection images are shown. Scale bar, 5 μm.See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

To elucidate the molecular basis of MbcT activity, we solved the high-resolution crystal structure of the MbcTA complex ([Figures 2](#fig2){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}A; [Table 1](#tbl1){ref-type="table"}). The complex adopts a donut-like structure composed of three heterotetrameric MbcTA complexes (\[MbcTA\]~2~). The oligomerization state and overall shape of the heterododecameric complex were validated by light scattering and by small-angle X-ray scattering (SAXS) ([Figures S3](#mmc1){ref-type="supplementary-material"}B--S3D; [Table 2](#tbl2){ref-type="table"}). MbcA folds into a single structured domain consisting of eight α helices, whereas Mb cT exhibits a β sandwich fold formed by six β strands arranged in two opposing antiparallel β sheets that are flanked and connected by nine α helices ([Figure 2](#fig2){ref-type="fig"}B). The lateral side of the substrate-binding pocket of MbcT is formed by a stretch of 11 amino acids arranged in a kinked loop pointing inward (α2-β2 loop) with the side chain of Arg47 extending from the tip of the loop. The main interactions in the MbcTA complex are between residues of the MbcA C terminus and residues, mostly arginines (R27, R33, R43, R47, R72), lining a deep central cleft in MbcT ([Figure 2](#fig2){ref-type="fig"}B). To validate the role of the C terminus of MbcA in sterically blocking access to the toxin active site, we designed a truncated MbcA version lacking the last ten C-terminal amino acids (residues 104--113). As expected, this variant was not able to neutralize the toxic effect of MbcT in a Mtb^ΔTA^ background ([Figure S3](#mmc1){ref-type="supplementary-material"}E).Figure 2Crystal Structure of the MbcTA Complex and Homology of MbcT to ARTs and NADases(A) Overall structure of the MbcTA heterododecamer consisting of three heterotetramers (3x\[MbcT-MbcA\]~2~) arranged around a 3-fold symmetry axis (as indicated by a black triangle). The dashed line box in the front view (left) represents one \[MbcT-MbcA\]~2~ heterotetramer formed by two MbcT (blue) and two MbcA (yellow) molecules as indicated in the side view (right).(B) Cartoon representation of the MbcTA complex and zoom-in of the putative NAD^+^-binding site. N and C termini and secondary structure elements are labeled (left). Part of the α2-β2 loop (G^45^GRW^48^) that lines the putative NAD^+^-binding site is displayed in red. Zoom (right): interactions based on a distance \<3.8 Å as calculated by the PISA server ([@bib34]) are indicated by dotted lines. The orientation of the MbcTA complex was modified to optimize visualization of the MbcT/MbcA interaction.(C) Structure-based alignment of the conserved active-site motifs found in three sequence regions of mono- and poly-ADP-ribosyltransferases (ARTs) and NAD^+^ glycohydrolases (NADases). The C-alpha atoms of Tyr28 in MbcT do not strictly superimpose with those of Tyr97 and Tyr907 in *D*tox and PARP1, respectively (see also D). Numbering of the residues refers to UniProt entries: MbcT (UniProt: Y1989), diphtheria toxin (*D*tox) (UniProt: [P00588](ncbi-n:P00588){#interref0010}), cholera toxin (*C*toxin) (UniProt: [P01555](ncbi-n:P01555){#interref0010k}), human poly \[ADP-ribose\] polymerase 1 (PARP1) (UniProt: [P09874](ncbi-n:P09874){#interref0010h}), the C-terminal toxin domain (tuberculosis necrotizing NAD^+^ glycohydrolase toxin TNT) of the Mtb outer membrane channel protein CpnT (UniProt: [O05442](ncbi-n:O05442){#interref0010l}), *P. aeruginosa* NAD^+^ glycohydrolase Tse6 (UniProt: [Q9I739](ncbi-n:Q9I739){#interref0010d}), and *Streptococcus pyogenes* NAD^+^ glycohydrolase SPN (UniProt: [D7S065](ncbi-n:D7S065){#interref0010s}).(D) Structural comparison of the active site in MbcT, *D*tox in complex with NAD^+^ (PDB: [1TOX](pdb:1TOX){#intref0205}), PARP1 (PDB: [4DQY](pdb:4DQY){#intref0210}), and CpnT (PDB: [4QLP](pdb:4QLP){#intref0215}). Conserved residues are colored according to their localization in the three distinct regions (cf. C).See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.Table 1Crystallographic Data Collection, Phasing, and Refinement StatisticsNative DatasetS-SAD Dataset**Data collection**Space groupP6~3~P6~3~Cell dimensions (Å,°)105.3, 105.3, 108.7105.3, 105.3, 108.790.0, 90.0, 12090.0, 90.0, 120Wavelength (Å)0.9762.479Resolution (Å)9.99--1.80 (1.86--1.80)[a](#tblfn1){ref-type="table-fn"}91.70--2.51 (2.61--2.51)R~merge~ (%)0.0562 (1.364)0.123 (0.667)I/σ(I)21.6 (1.5)42.5 (7.3)Completeness (%)98.8 (90.2)89.3 (70.3)Redundancy10.0 (7.5)57.6 (49.2)CC~1/2~0.999 (0.497)0.999 (0.920)Total number of reflections620,194 (42,332)1,225,773 (92,688)Unique reflections62,157 (5,639)21,269 (1,882)**Refinement**R~work~ (%)16.23 (27.26)--R~free~ (%)21.11 (31.28)--**No. atoms**Total4,865--Macromolecules4,569--Ligands18--Waters278--No. protein residues589--**B-factors**[b](#tblfn2){ref-type="table-fn"}**(Å2)**Macromolecules42.4--Solvent62.8--**RMSD**[b](#tblfn2){ref-type="table-fn"}Bond lengths (Å)0.007--Bond angles (°)0.990--Ramachandran[c](#tblfn3){ref-type="table-fn"} (%)Most favored99.0--Allowed1.0--Outliers0.0--[^7][^8][^9]Table 2SAXS Data Collection and Derived ParametersMbcTA**Data collection**InstrumentP12 at EMBL/DESY, storage ring PETRA III, GermanyBeam geometry0.2 × 0.12 mm^2^Wavelength (Å)1.24*q*-range (Å^−1^)0.008--0.47Exposure time (ms)20 × 50Concentration range (mg mL^−1^)0.6--7.1Temperature (K)283**Structural parameters**[a](#tblfn4){ref-type="table-fn"}*I*(0) (arbitrary units) (from *P*(*r*))31,320 ± 10*R*~*g*~ (from *P*(*r*)) (Å)41 ± 1*I*(0) (arbitrary units) (from Guinier)31,340 ± 30*R*~*g*~ (Å) (from Guinier)41 ± 1*D*~*max*~ (Å)114Porod volume (10^3^ Å^3^)262**Molecular mass determination**[a](#tblfn4){ref-type="table-fn"}MM~*POROD*~ (from Porod volume) (kDa)154 ± 15MM~*saxs*~ (from *I*(0), kDa)110 ± 20MM~DAM~ (from bead model, kDa)170 ± 35Calculated monomeric MM from sequence (kDa)197.2**Software employed**Primary data reductionAutomated radial averagingData processingPRIMUS*Ab initio* analysisDAMMINValidation and averagingSASRES, DAMAVERComputation of model intensitiesCRYSOLSASBDB entry codeSASDD33[^10]

The closest structural relatives to MbcT are ADP-ribosyltransferases (ARTs), in particular bacterial ART toxins and poly (ADP-ribose) polymerases (PARPs) ([@bib2], [@bib45], [@bib57]) ([Figure S4](#mmc1){ref-type="supplementary-material"}A). ARTs catalyze the transfer of an ADP-ribose group from an NAD^+^ donor molecule to a substrate (proteins, DNA, or RNA) and release free nicotinamide (NAA). Bacterial ART toxins are classified into two major groups based on conserved active-site motifs distributed across three regions. The diphtheria toxin (ARTD) group has an H-Y/Y-E motif, also found in PARPs, whereas the cholera toxin (ARTC) group contains an R-S-E motif ([@bib2], [@bib57]) ([Figure 2](#fig2){ref-type="fig"}C). The structural hallmark of ARTs is a central cleft bearing a conserved NAD^+^-binding pocket ([@bib2], [@bib23]). An NAD^+^-binding pocket is also present in NAD^+^ glycohydrolases (NADases), such as the bacterial exotoxins TNT ([@bib61]), SPN ([@bib18]), and Tse6 ([@bib74]), but the overall structural homology of MbcT with NADases is less obvious ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Structural superimposition with selected ARTs and NADases suggests that MbcT could consume NAD^+^ as well, and pinpoints Arg27 in region 1, and Tyr28 and Tyr58 in region 2, as potential NAD^+^-binding residues ([Figures 2](#fig2){ref-type="fig"}C and 2D). Yet, the region-3 residue, which is thought to confer substrate recognition and specificity, is replaced by a glycine (Gly^152^) in MbcT ([Figure 2](#fig2){ref-type="fig"}C). To investigate the functional importance of the putative NAD^+^-binding site of MbcT and the potential catalytic function of the RES motif (R47-E69-S126), we substituted single residues of MbcT to alanine and assessed the effect on growth inhibition of Mtb^ΔTA^. Non-toxic MbcT-R27A, MbcT-R47A, and MbcT-Y58A mutants did not affect the growth of Mtb^ΔTA^ or *E. coli*, thus establishing the crucial role of these individual residues for MbcT-catalyzed growth inhibition ([Figures S4](#mmc1){ref-type="supplementary-material"}B and S4C). Surprisingly, Ser126 was not essential for toxicity, whereas MbcT-Y28A and MbcT-E69A retained limited toxin activity. Taken together, these results suggest that MbcT toxicity involves NAD^+^, but that the catalytic mechanism underlying toxin activity is divergent from that of ART enzymes and NADases.

To identify substrates of MbcT and explore its NAD^+^-binding activity *in vitro*, we sought to purify the WT, recombinant MbcT protein. To overcome cell toxicity, we co-expressed full-length WT MbcT with a His-tagged, C-terminal truncation of MbcA (MbcA^Δ112--113^). WT MbcT is only weakly associated with His-MbcA^Δ112--113^, allowing for subsequent isolation of WT MbcT by salt-induced dissociation of the His-MbcA^Δ112--113^-MbcT complex ([Figure S5](#mmc1){ref-type="supplementary-material"}A). In addition to WT MbcT, we also purified the MbcT active-site mutant R27E (MbcT-R27E) from *E. coli* as a control ([Figures S5](#mmc1){ref-type="supplementary-material"}B and S5C). This variant of MbcT was non-toxic to Mtb^ΔTA^ cells ([Figure S5](#mmc1){ref-type="supplementary-material"}D). We then incubated recombinant protein with different bacterial cell fractions in the presence of ^32^P-labeled NAD^+^ to probe for ADP-ribosylation of cellular protein but did not detect ^32^P-ADP-ribose-incorporation into the protein fractions ([Figure S5](#mmc1){ref-type="supplementary-material"}E). MbcT also did not modify nucleic acid substrates, in contrast to the mycobacterial DNA-modifying TA toxin DarT ([@bib27]) ([Figure S5](#mmc1){ref-type="supplementary-material"}F).

In addition to NAD^+^ degradation and ADP-ribose (Appr) production, we observed the appearance of an unknown reaction product, dependent on the MbcT concentration ([Figure 3](#fig3){ref-type="fig"}A). Interestingly, supplementing the MbcT reaction buffer with sodium phosphate markedly enhanced NAD^+^ degradation into NAA and the hitherto unknown reaction product ([Figure 3](#fig3){ref-type="fig"}B), whereas the MbcT R27E mutant or the MbcTA complex did not trigger NAD^+^-turnover ([Figures 3](#fig3){ref-type="fig"}B and [S5](#mmc1){ref-type="supplementary-material"}F). We performed high resolution mass spectrometry and nuclear magnetic resonance experiments, which identified the additional reaction product as ADP-ribose-1″-phosphate (Appr1p; \[M-H\]^−^ m/z = 638.0301) ([Figure 3](#fig3){ref-type="fig"}C). To our knowledge, MbcT represents the first reported enzyme with NAD^+^ phosphorylase activity ([Figure 3](#fig3){ref-type="fig"}D).Figure 3Enzymatic Activity of MbcT(A) Representative autoradiograph of a TLC plate showing MbcT-mediated depletion of ^32^P-NAD^+^ over time and simultaneous accumulation of ^32^P-ADP-ribose (Appr) and a secondary reaction product (white arrow). The dotted line indicates the position where samples were applied to the plate. Similar results were obtained in two independent experiments.(B) Representative HPLC chromatograms of the reaction products of NAD^+^ (0.5 mM) with MbcT (0.7 μM) in the presence (orange) or absence (black) of sodium phosphate (30 mM). The white arrow indicates the reaction product formed in addition to nicotinamide (NAA) (cf. A). MbcT-R27E does not degrade NAD^+^ in sodium phosphate (30 mM) buffer (gray line). NAD^+^, Appr and NAA were identified by retention time comparisons with standards. The observed Appr is an impurity found in the commercial substrate. Similar results were obtained in three independent experiments.(C) ^1^H-^31^P HSQC^31^ spectra of the reaction products of NAD^+^ (5 mM) with MbcT (10 mM) and, for reference, of pure Appr (5 mM). Phosphate atoms from the ADP-ribose moiety are colored green, whereas the phosphate atom derived from orthophosphate is highlighted in orange.(D) Proposed reaction mechanism of MbcT-mediated NAD^+^ phosphorolysis yielding ADP-ribose-1″-phosphate (Appr1p) and NAA.(E) Kinetics of NAD^+^ phosphorolysis by MbcT (50 nM). K~m~ and V~max~ values were determined by nonlinear regression analysis with the Michaelis-Menten equation.(F) Comparison of initial velocity (*V*~0~) of NAD^+^ phosphorolysis of WT MbcT (50 nM) and MbcT-R27E (50 nM) in the presence or absence of sodium phosphate (50 mM). The initial velocities were determined at a substrate concentration of 100 μM. For data in (E) and (F), data are represented as mean of eight and four independent replicates ± SD, respectively.See also [Figures S5](#mmc1){ref-type="supplementary-material"} and [S6](#mmc1){ref-type="supplementary-material"}.

A kinetic analysis of MbcT activity, based on NAD^+^ consumption at saturating orthophosphate conditions, yielded a K~m~ of 110 ± 8 μM ([Figure 3](#fig3){ref-type="fig"}E). The turnover number of MbcT for NAD^+^ phosphorolysis (k~cat~) was 167 ± 3 s^−1^ ([Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B). By contrast, MbcT-R27E did not show any detectable NAD^+^ turnover establishing the essentiality of Arg27 for NAD^+^ phosphorolysis ([Figure 3](#fig3){ref-type="fig"}F). With a catalytic efficiency (k~cat~/K~m~) of 1.5 × 10^6^ M^−1^s^−1^, MbcT is one of the most effective NAD^+^-degrading toxins characterized to date, more potent than diphtheria toxin (5 × 10^5^ M^−1^s^−1^) ([@bib47]) and the mycobacterial NADase TNT (8.4 × 10^4^ M^−1^s^−1^) ([@bib61]). The high catalytic efficiency of MbcT implies that this enzyme has specifically evolved to carry out NAD^+^ phosphorolysis.

To determine whether MbcT exerts its toxic effect via NAD^+^ turnover, we measured the levels of NAD^+^ in Mtb^ΔTA^ expressing *mbcT*. We observed rapid depletion of intracellular NAD^+^ upon induction of *mbcT* expression, whereas control strains expressing no toxin or the MbcT-R27E inactive mutant exhibited no decrease in intracellular NAD^+^ levels ([Figure 4](#fig4){ref-type="fig"}A). We also exploited the *mbcT*-inducible system described above to evaluate MbcT toxicity *in vivo*. First, we showed that, unlike TNT ([@bib61]), ectopic expression of *mbcT* in WT Mtb had no deleterious effect on infected human monocyte-derived macrophages (hMDM) ([Figure 4](#fig4){ref-type="fig"}B). We then infected hMDM with Mtb^ΔTA^ transformed with a control vector or a plasmid carrying ATc-inducible *mbcT.* Induction of *mbcT* expression 2 days after infection resulted in more than a 10-fold decrease in the intracellular bacterial load ([Figure 4](#fig4){ref-type="fig"}C). Next, we infected immune-deficient SCID mice, which are highly sensitive to Mtb infection, with the same Mtb^ΔTA^ strain. Doxycycline-mediated induction of *mbcT* after Mtb^ΔTA^ infection prolonged the survival of infected mice by ∼40% compared to controls without doxycycline ([Figure 4](#fig4){ref-type="fig"}D).Figure 4MbcT Activity Can Be Bactericidal *In Vivo*(A) Relative intracellular NAD^+^ levels were measured in Mtb^ΔTA^ cells transformed with empty vector (Ctrl) or with pGMC derivatives expressing WT MbcT or MbcT*-*R27E, as indicated. Cultures were grown in the absence (−ATc) or presence of ATc (+ATc) to induce *mbcT* gene expression from the P1 promoter. Cellular NAD^+^ was extracted 24 h after induction and measured by a coupled bioluminescence assay. Data are represented as mean of three independent replicates ± SD.(B) Viability of human macrophages infected with WT Mtb strains carrying a pGMC-TetR-P1-*mbcT* construct (MbcT), was measured by flow cytometry after labeling with Zombie Aqua Viability Kit. Infected macrophages were cultivated in the presence (+ATc) or absence of ATc (−ATc) to induce *mbcT* gene expression. Mtb^ΔTA^ carrying an empty vector was included as control (Ctrl). Data are represented as mean of three independent replicates ± SD.(C) ATc-induction of *mbcT* in Mtb^ΔTA^ results in mycobacterial killing inside human monocyte-derived macrophages. Cells were infected at a multiplicity of infection of 0.1 bacteria/cell with Mtb^ΔTA^ strains carrying pGMC-TetR-P1-*mbcT* (*mbcT*) or empty vector (Ctrl). Toxin expression was induced 2 days of infection by addition of ATc, when indicated.(D) ATc-induction of *mbcT* expression in Mtb^ΔTA^ reduces mycobacterial virulence and improves host survival in immune-deficient SCID mice. Mice were infected with Mtb^ΔTA^ strains transformed with pGMC-TetR-P1-*mbcT* (*mbcT*) or empty vector (Ctrl). Toxin expression was induced by addition of doxycycline (Doxy) in the drinking water of the animals from 7 days onward prior to infection. Mouse survival was followed over time using ten mice per condition. Statistical analysis was performed using the log-rank (Mantel-Cox) test (^∗∗∗∗^\<0.0001).(E) Number of CFU isolated from the lungs of immune-competent C57BL/6 mice infected with Mtb^ΔTA^ carrying pGMC-TetR-P1-*mbcT* (*mbcT*) or empty vector (Ctrl). At day 21, mice were given isoniazid (INH) or Doxy by daily gavage for 10 days, as indicated. Data are represented as mean of at least four independent replicates ± SD (n = 4--8 mice/group). NS or stars indicate significance as determined by a Student's t test (^∗^\<0.05; ^∗∗^\<0.01; ^∗∗∗^\<0.001).

In addition, we infected immune-competent C57BL/6 mice with the same bacterial strains and induced *mbcT* expression with doxycycline 21 days after infection. At this stage, the Mtb load in the lungs reaches a plateau. MbcT induction resulted in the potent killing of Mtb (5-fold reduction in CFUs). Further, MbcT enhanced the therapeutic efficacy of the frontline anti-TB drug isoniazid (INH). Treatment with INH alone led to a 10-fold reduction in CFU relative to untreated mice, whereas INH treatment combined with *mbcT* expression led to a 100-fold reduction in CFUs, indicative of a synergistic effect ([Figure 4](#fig4){ref-type="fig"}E). These results indicate that MbcT is highly toxic to Mtb *in vivo* when not neutralized by MbcA. As such, small inhibitory molecules able to dislocate the MbcTA complex could be promising candidates for the development of novel therapeutics to control Mtb infection.

The molecular mechanism underpinning MbcT toxicity, NAD^+^ phosphorolysis, is unprecedented for TA modules. To our knowledge, MbcTA is also the first TA system that degrades an essential cellular metabolite resulting in rapid cell death. Yet, the biological role of the MbcTA system remains elusive. We did not detect any particular phenotype in our MbcTA-KO mutant in a variety of stress conditions *in vitro* and *in vivo* (data not shown), so the relevance of the MbcTA system in the Mtb life cycle is difficult to anticipate. This might be because this system would need to be inactivated together with other TA pairs in order to observe a phenotype, as reported for MazEF TA pairs ([@bib65]), or because we did not expose the Mtb^ΔTA^ mutant to the relevant physiological stress.

Strikingly, the Mycobacterium phage Ibhubesi encodes a MbcA homolog, namely PBI_IBHUBESI_52 ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C). It is tempting to speculate that the *mbcT-mbcA* TA system was acquired by Mtb, and possibly other bacteria, to inhibit bacteriophage propagation by triggering self-intoxication, reminiscent of abortive infection TA systems ([@bib12]). In line with this, mycobacteriophage Ibhubesi could have acquired the IBHUBESI_52 gene to neutralize the bacterial defense. The IBHUBESI_52 protein would then be an antidefense protein, mechanistically different but functionally similar to the Gp4.5 protein of bacteriophage T7 ([@bib54]). Whether TA systems are indeed capable of inducing altruistic killing to prevent phage attack is still under debate ([@bib60]). Further experiments are needed to test this hypothesis.

Our study identifies MbcT as a highly efficient NAD^+^ phosphorylase. Further, we show that MbcT activity can be bactericidal in Mtb, in line with previous reports demonstrating that *mbcA* is an essential gene ([@bib9]), and NAD^+^ depletion is lethal in mycobacteria ([@bib32], [@bib51], [@bib71]). During the revision process of this paper, [@bib58] reported that plasmid-based expression of three prokaryotic RES-domain containing toxins, including MbcT, resulted in growth arrest of *E. coli*. Interestingly, the RES toxin from *Photorhabdus luminescens* (RES^*Pl*^) triggers depletion of intracellular NAD^+^ upon expression in *E. coli*. Although the enzymatic activity of RES^*Pl*^ has not been biochemically validated, it supports our hypothesis that NAD^+^ degradation is a more general mechanism utilized by prokaryotic TA toxin systems to interfere with bacterial growth. The authors also report the crystal structure of a RES toxin in complex with its cognate Xre antitoxin from *Pseudomonas putida* (RES^*Pp*^-Xre^*Pp*^), in which the individual TA components share significant structural similarity with MbcT and MbcA, respectively. The putative NAD^+^ binding pocket of the RES^*Pp*^ toxin is blocked by the C-terminal region of the Xre antitoxin as observed in the MbcTA complex, further highlighting the functional similarities within the RES-Xre TA systems. However, the toxin and antitoxin proteins assemble into complexes with a different quaternary structure, namely a heterohexameric (RES^*Pp*^)~2~-(Xre^*Pp*^)~4~ complex opposed to the heterododecameric MbcT~6~-MbcA~6~ complex.

To conclude, our findings pave the way for future exploration of NAD^+^ phosphorylases in other organisms, and for functional studies of this new class of enzymes in the context of bacterial metabolism. This work also enables the search for small molecule inhibitors that disrupt the MbcTA complex or inactivate the MbcA antitoxin ([@bib75]), which could be used in combination with standard drug regimens to combat TB, the most devastating infectious disease globally. More generally, identifying and targeting bactericidal TA systems in bacterial pathogens might illuminate approaches to treat other infectious diseases.
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Key Resources Table {#sec3.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Anti-GroEL (*E. coli*) monoclonal antibody (clone 9A1/2)Enzo Life SciencesCat\# ADI-SPS-870-D; RRID: [AB_2039163](nif-antibody:AB_2039163){#intref0010}**Bacterial and Virus Strains***Escherichia coli* DH5αThermo Fisher ScientificCat\# 18265017*Escherichia coli* BL21(DE3) CodonPlus-RILAgilentCat\# 230240*Escherichia coli* W3110Genevaux laboratory [@bib25]N/A*Mycobacterium smegmatis* mc^2^155 groEL1ΔC[@bib42]N/A*Mycobacterium tuberculosis* H37RvATCCATCC 27294*Mycobacterium tuberculosis* H37Rv Δ(Rv1990c-Rv1989c)::Kan^R^This studyN/A**Chemicals, Peptides, and Recombinant Proteins**Nicotinamide adenine dinucleotide \[adenylate-32P\]Hartmann AnalyticCat\# ARP0141Q5 High Fidelity PolymeraseNEBCat\# M0491Anhydrotetracycline hydrochlorideMerckCat\# 37919Doxycycline hydrochlorideMerckCat\# D3447DNase IThermo Fisher ScientificCat\# AM2222Superscript III Reverse transcriptaseThermo Fisher ScientificCat\# 18080044SYBER Green qPCR Premix ex TaqOzymeCat\# TAKRR420AThrombin proteaseSigma-AldrichCat\# T4648Protease-Inhibitor Mix HPServaCat\# 39106Deoxyribonuclease ISigma-AldrichCat\# DN25Complete EDTA-free protease inhibitor cocktailSigma-AldrichCat\# 11873580001Recombinant protein: TEV proteaseM. Wilmanns labN/ARecombinant protein: *M. tuberculosis* H37Rv MbcAThis study[NP_216506.1](ncbi-p:NP_216506.1){#intref0015}Recombinant protein: *M. tuberculosis* H37Rv MbcTThis study[NP_216505.1](ncbi-p:NP_216505.1){#intref0020}Recombinant protein: *M. tuberculosis* H37Rv MbcT-R27E (aa 1--186, ref\# NP_216505.1)This studyN/A**Critical Commercial Assays**NAD/NADH-Glo Detection ReagentPromegaCat\# G9071LIVE/DEAD BacLight Bacterial Viability KitsThermo Fisher ScientificCat\# L7007Zombie Aqua Fixable Viability KitBioLegendsCat\# 423101RNeasy mini kitQIAGENCat\# 74104RNeasy Protect Bacteria Mini KitQIAGENCat\# 74524Penta His HRP conjugate kitQIAGENCat\# 34460DNeasy Blood & Tissue kitQIAGENCat\# 69504**Deposited Data**Raw image dateThis study; Mendeley Data<https://doi.org/10.17632/y6ynjm5sf3.1>MbcT/MbcA structureThis paperPDB: [6FKG](pdb:6FKG){#intref0030}MbcT/MbcA SAXS dataThis paperSASBDB: SASDD33**Experimental Models: Cell Lines**Primary Human monocytes from healthy donorsEtablissement Français du SangContract Nr. 121/PVNT/TOU/IPBS01/2009-0052**Experimental Models: Organisms/Strains**Mouse: SCID CB17/Icr-Prkdcscid/IcrIcoCrlCharles RiverRRID: IMSR_CRL:236Mouse: C57BL/6JCharles RiverRRID: IMSR_JAX:000664**Oligonucleotides**See [Table S1](#mmc1){ref-type="supplementary-material"} for list of primers used in this studyN/AN/A**Recombinant DNA**See [Table S2](#mmc1){ref-type="supplementary-material"} for list of plasmids used in this studyN/AN/A**Software and Algorithms**SMART[@bib35]RRID: [SCR_005026](rridsoftware:SCR_005026){#intref0035}Jalview 2.10[@bib73]RRID: [SCR_006459](rridsoftware:SCR_006459){#intref0040}Pymol 2.1.1SchrödingerRRID: [SCR_000305](rridsoftware:SCR_000305){#intref0045}Prism 8Prism<https://www.graphpad.com/scientific-software/prism/>OmniSECMalvern Panalytical<https://www.malvernpanalytical.com/en/>MassHunter B.07.00AgilentRRID: [SCR_015040](rridsoftware:SCR_015040){#intref0060}OpenLAB CDS ChemStationAgilentRRID: [SCR_015742](rridsoftware:SCR_015742){#intref0065}Topspin 3.5BrukerRRID: [SCR_014227](rridsoftware:SCR_014227){#intref0070}7500 Real-time PCR Software v2.3Thermo Fisher ScientificRRID: [SCR_014596](rridsoftware:SCR_014596){#intref0075}XDS/XSCALE[@bib29]RRID: [SCR_015652](rridsoftware:SCR_015652){#intref0080}CCP4 suite[@bib76]RRID: [SCR_007255](rridsoftware:SCR_007255){#intref0085}SHELX[@bib56]RRID: [SCR_014220](rridsoftware:SCR_014220){#intref0090}ARP/wARP[@bib48]<http://www.embl-hamburg.de/ARP/>REFMAC[@bib69]RRID: [SCR_014225](rridsoftware:SCR_014225){#intref0100}PHENIX[@bib1]RRID: [SCR_014224](rridsoftware:SCR_014224){#intref0105}PDB_REDO[@bib28]<https://pdb-redo.eu/>TLSMD[@bib44][http://skuld.bmsc.washington.edu/∼tlsmd/](http://skuld.bmsc.washington.edu/%7Etlsmd/){#intref0115}Coot[@bib14]RRID: [SCR_014222](rridsoftware:SCR_014222){#intref0120}Molprobity[@bib6]RRID: [SCR_014226](rridsoftware:SCR_014226){#intref0125}ATSAS 2.7[@bib49]RRID: [SCR_015648](rridsoftware:SCR_015648){#intref0130}PDBeFOLD[@bib34]<http://www.ebi.ac.uk/msd-srv/ssm/>ImageJ<https://imagej.net/Welcome>RRID: [SCR_003070](rridsoftware:SCR_003070){#intref0145}FlowJoFlowJoRRID: [SCR_008520](rridsoftware:SCR_008520){#intref0150}
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Further information and requests for reagents may be directed to, and will be fulfilled by the Lead Contact, Annabel Parret (<ahaparret@gmail.com>).

Experimental Model and Subject Details {#sec3.3}
--------------------------------------

### Bacterial strains {#sec3.3.1}

*M. smegmatis* mc^2^155 groEL1ΔC and *M. tuberculosis* H37Rv (WT) and Mtb mutant strains were routinely grown at 37°C in Middlebrook 7H9 medium (Difco) supplemented with 10% albumin-dextrose-catalase (ADC, Difco) and 0.05% Tween 80 (Sigma-Aldrich) or on Middlebrook 7H11 agar medium (Difco) supplemented with 10% oleic acid-albumin-dextrose-catalase (OADC, Difco). When required, kanamycin (50 μg ml^−1^), hygromycin (50 μg ml^−1^), streptomycin (25 μg ml^−1^) or zeocin (25 μg ml^−1^) were added to the culture media. *E. coli* strains DH5α, (DE3) CodonPlus RIL and W3110 ([@bib25]) were grown at 37°C in LB (DH5α; W3110) or Terrific Broth medium (Melford) ((DE3) CodonPlus RIL) supplemented with kanamycin (30 μg ml^−1^), chloramphenicol (34 μg ml^−1^) or ampicillin (100 μg ml^−1^) when required. Induction of gene expression is detailed in the [Method Details](#sec3.4){ref-type="sec"} section.

### Human Cell Culture {#sec3.3.2}

Human monocytes were obtained from healthy blood donors (Etablissement Français du Sang, EFS, Toulouse, France) with written informed consent (under EFS Contract n°121/PVNT/TOU/IPBS01/2009-0052, which was approved by the French Ministry of Science and Technology, agreement nr. AC2009-921, following articles L1243-4 and R1243-61 of the French Public Health Code). Monocytes were prepared following a previously published procedure ([@bib67]). Briefly, cells were purified using CD14 microbead positive selection and MACS separation columns (Miltenyi Biotec), according to manufacturer's instructions. For differentiation of monocyte-derived macrophages, monocytes were allowed to adhere to glass coverslips (VWR international) in 6-well plates (ThermoFischer Scientific), at 1.5x10^6^ cells/well, for 1 h at 37°C in pre-warmed RPMI-1640 medium (GIBCO). The medium was then supplemented with 10% Fetal Bovine Serum (Sigma-Aldrich), 1% sodium pyruvate (GIBCO), 0.1% β-mercaptoethanol (GIBCO) and 20 ng ml^−1^ human Macrophage Colony-Stimulating Factor (Miltenyi Biotec). Cells were allowed to differentiate for seven days at 37°C under 5% CO~2~ atmosphere.

### Experimental animals {#sec3.3.3}

C57BL/6J and SCID CB17/Icr-Prkdcscid/IcrIcoCrl mice were purchased from Charles River and maintained under specific germ-free conditions in the IPBS specific animal facility at 22°C under a 12 h light/dark cycle for at least one week before starting experiments. All animal experiments were performed in animal facilities that meet all legal requirements in France and by qualified personnel in such a way to minimize discomfort for the animals. All procedures including animal studies were conducted in strict accordance with French laws and regulations in compliance with the European community council directive 68/609/EEC guidelines and its implementation in France. All protocols were reviewed and approved by the Comité d'Ethique Midi-Pyrénées (reference MP/03/07/04/09) and the Comité d'Ethique FRBT (APAFIS\#1269).

Method Details {#sec3.4}
--------------

### Protein homology searches {#sec3.4.1}

Rv1989c-Rv1990c-like TA systems were identified in bacterial genomes using NCBI's standard protein BlastP searches against the non-redundant protein sequence (nr) database. Hits from *M. tuberculosis* genomes were excluded. From the resulting top 100 hits, only those homologs were withheld for which the hypothetical toxin and antitoxin were encoded by adjacent genes. Selected protein sequences were retrieved from the UniProt database and re-aligned using MAFFT ([@bib30]) within the Jalview software package ([@bib73]). Pairwise protein sequence identities were calculated using the Pairwise Alignment tool in Jalview. Conserved protein were identified with InterPro ([@bib16]). The N-terminal HTH domain of the antitoxin, which is not detected by InterPro, was identified using the HTH motif prediction program available from the NPS@ web server ([@bib8]).

### *E. coli* viability assays {#sec3.4.2}

*E. coli* strain W3110 containing p29SEN or p29SEN-Rv1990c was co-transformed with empty vector (pMPMK6) or pMPMK6-Rv1989c ([Table S2](#mmc1){ref-type="supplementary-material"}), grown to mid-log phase, serially diluted and spotted on agar plates supplemented with appropriate antibiotics. 1% arabinose or 5 μM IPTG or were used to induce expression of Rv1989c and Rv1990c, respectively. Images were taken after overnight incubation at 37°C. Raw images are available on Mendeley Data (<https://doi.org/10.17632/y6ynjm5sf3.1>).

### Construction of *M. tuberculosis* mutants {#sec3.4.3}

Mutant strains of *M. tuberculosis* H37Rv were constructed by allelic exchange using recombineering ([@bib70]). Briefly, two ∼0.5-kb DNA fragments flanking the *mbcA-mbcT* operon were amplified by PCR from *M. tuberculosis* H37Rv genomic DNA, using the primers set 1990cAm-Fw/1990cAm-Rv or 1990cAv-Fw/1990cAv-Rv, respectively. These two DNA fragments were inserted into pGem5Z (Promega) flanking a kanamycin-resistance cassette. The recombination substrate was recovered by enzymatic digestion and agarose gel purifications. The recipient strain for recombineering was a derivative of *M. tuberculosis* H37Rv carrying two plasmids: the integrative plasmid pGMCS-P1-Rv1990c, constitutively expressing *mbcA*, and pJV53H, a hygromycin-resistant pJV53-derived plasmid expressing recombineering enzymes ([@bib70]) ([Table S2](#mmc1){ref-type="supplementary-material"}). This strain was grown in growth medium supplemented with hygromycin until mid-log phase and expression of recombineering enzymes was induced by 0.2% acetamide (Sigma-Aldrich) overnight at 37°C. After induction, electrotransformation was performed with 100 ng of the linear DNA fragment for allelic exchange. After 48 h incubation at 37°C, mycobacteria were plated onto agar plates supplemented with kanamycin. Kanamycin-resistant clones were harvested, cultured in growth medium supplemented with kanamycin and verified to carry the expected allele replacement by colony PCR, using appropriate primers. The pJV53H plasmid was spontaneously lost by serial rounds of culture without hygromycin. Plasmid pGMCS-P1-Rv1990c was removed by transformation with pGMCZ, a similar vector but carrying resistance to zeocin, resulting in the deleted strain WT Mtb Δ(Rv1990c-Rv1989c)::Kan^R^ /pGMCZ, further abbreviated as Mtb^ΔTA^.

### Cloning of expression constructs {#sec3.4.4}

#### M. tuberculosis expression constructs {#sec3.4.4.1}

Rv1989c, Rv1990c or both genes were amplified by PCR using Mtb H37Rv genomic DNA as template and primer pairs clo-rv1990-attB2/clo-Rv1990-attB3, clo-rv1989-attB2/clo-Rv1989-attB3 or clo-rv1990-attB2/clo-Rv1989-attB3, respectively ([Tables S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}). Plasmids pGMCS-TetR-P*1-*Rv1990c, pGMCS-TetR-P1-Rv1989c or pGMCS-TetR-P1-Rv1990c-Rv1989c were constructed by multisite gateway recombination ([@bib55]), using plasmid pDE43-MCS as destination vector. These plasmids are integrative vectors (insertion at the attL5 mycobacteriophage insertion site in the *glyV* tRNA gene) and express Rv1990c, Rv1989c or Rv1990c-Rv1989c under the control of P1, a tetracycline-inducible promoter ([@bib13]) ([Table S2](#mmc1){ref-type="supplementary-material"}). In pGMCS-TetR-P1-Rv1990c and pGMCS-TetR-P1-Rv1990c-Rv1989c, the sequence harboring the natural Shine-Dalgarno sequence of Rv1990c (AGGAAGACAGGCTGCCC) was placed upstream of the AUG codon of Rv1990c. In pGMCS-TetR-P1-Rv1989c, this same sequence was placed upstream of the GUG start codon of the Rv1989c single open reading frames (see sequence of oligonucleotide clo-rv1989c-B2 in [Table S1](#mmc1){ref-type="supplementary-material"}). The empty vector pGMC-TetR-P1 was also constructed by multisite gateway recombination, but with no gene inserted in front of the P1 promoter.

Generation of a construct for expression of Rv1989c and Rv1990c lacking the last ten codons (pGMCS-TetR-P1-ΔRv1990c(104-113)-Rv1989c) was achieved by PCR amplification of two overlapping DNA fragments using pGMCS-TetR-P1-Rv1990c-Rv1989c as template and the primer pairs clo-rv1990-attB2/1990c-del104_113-Rv or 1990c-del104_113-Fw/clo-rv1989-attB3 ([Table S2](#mmc1){ref-type="supplementary-material"}). The two purified fragments were mixed and used as template for a second round of PCR with the oligonucleotide pair clo-rv1990-attB2/clo-Rv1989-attB3. The final construct was generated by multiple gateway cloning using the resulting purified PCR fragment.

Directed mutagenesis of Rv1989c was performed by PCR amplification of two overlapping DNA fragments carrying the required mutation using pGMCS-TetR-P1-Rv1989c as template and the primer pair clo-rv1989-attB2/Rv1989c_XnA_rev or Rv1989c_XnA_for/clo-rv1989-attB3 ([Table S2](#mmc1){ref-type="supplementary-material"}). Purified PCR fragments were mixed and used as templates for a second round of PCR with the primer pair clo-rv1989-attB2/clo-Rv1989-attB3. The resulting fragments were used for multiple gateway cloning to construct pGMCS-TetR-P1-Rv1989c derivatives with the desired mutations.

#### M. smegmatis expression constructs {#sec3.4.4.2}

The Rv1990c-Rv1989c operon was PCR-amplified using Q5 High Fidelity Polymerase (New England Biolabs) from Mtb H37Rv genomic DNA using the primer set Rv1990c_NcoI and Rv1989c_HindIII ([Table S2](#mmc1){ref-type="supplementary-material"}). DNA fragments were ligated into pMyNT ([Table S1](#mmc1){ref-type="supplementary-material"}) using NcoI/HindIII restriction enzymes, generating pMyNT-MbcTA encoding N-terminally His~6~-tagged MbcA and untagged MbcT.

#### *E. coli* expression constructs {#sec3.4.4.3}

Rv1989*c* and Rv1990c were PCR-amplified using Phusion High-Fidelity DNA polymerase (New England Biolabs) from *M. tuberculosis* H37Rv genomic DNA and ligated into expression vectors pnEK and pnEA-His, respectively, using NdeI/BamHI restriction enzymes ([Table S2](#mmc1){ref-type="supplementary-material"}). Resulting constructs, pnEK-MbcT and pnEA-His-MbcA^Δ112−113^, encoding untagged MbcT and N-terminally His~6~-tagged MbcA^Δ112−113^ were cloned using primers DF101/DF102 and SpeI/XbaI ligation of a synthetic fragment consisting of MbcA^Δ112−113^ (gBlock; Integrated DNA Technologies), respectively. the *mbcT* gene was first cloned in pET-28a(+) using restriction enzymes NcoI/HindIII. MbcT mutants (pET-28a(+)-MbcT constructs) were generated by site-directed mutagenesis ([Table S2](#mmc1){ref-type="supplementary-material"}). To generate constructs for the *E. coli* toxicity rescue assays, Rv1989c was PCR-amplified using Phusion High-Fidelity DNA polymerase (New England Biolabs) with primers for1989-2 and rev1989-2. The PCR product was cloned as an EcoRI/HindIII fragment under the control of an arabinose-inducible promoter (pBAD) into pMPMK6 vector ([@bib39]) digested with the same enzymes ([Table S2](#mmc1){ref-type="supplementary-material"}). The *mbcA* gene was PCR-amplified using Phusion High-Fidelity DNA polymerase (New England Biolabs) using primers for1990-2 and rev1990-2, and cloned as an EcoRI/HindIII fragment under the control of an IPTG-inducible promoter into p29SEN vector ([@bib17]) digested with the same enzymes. *E. coli* strain DH5α was used for all cloning experiments.

### Viability Staining and Flow Cytometry {#sec3.4.5}

Exponentially growing cultures (OD~600~ between 0.05 and 0.2) of strain Mtb^ΔTA^ containing plasmid pGMCS-TetR-P1 (empty vector) or pGMCS-TetR-P1-Rv1989c were divided in two: half was left in standard growth medium (uninduced cultures) and the other half was treated with 200 ng ml^−1^ of anhydrotetracycline (ATc) to induce expression from the P1 promoter. After various times post-induction, samples were harvested and centrifuged to remove residual ATc. Cells were resuspended in PBS buffer and dilutions were plated on 7H11 OADC agar, to measure colony-forming units. For labeling with LIVE/DEAD *Bac*Light (Molecular Probes) dyes, cells were harvested 4 days post-ATc induction. Cells were centrifuged, resuspended in PBS buffer and stained as recommended by the manufacturer. Labeled cells were either observed by confocal microscopy using an Andor/Olympus spinning disk microscope with an Olympus 100x oil immersion objective or by fluorescence-activated cell sorting using a BD FACS Aria Fusion flow cytometer. Image analysis was performed using ImageJ software and flow cytometry data analysis using FlowJo software. Raw images are available on Mendeley Data (<https://doi.org/10.17632/y6ynjm5sf3.1>).

### RT-qPCR {#sec3.4.6}

RT-qPCR quantification of *mbcT* mRNA was performed on total RNA extracted from Mtb WT cultures grown to exponential phase (OD~600~ of 0.5) at 37°C in 7H9 + 10% ADC + 0.05% Tween-80. For samples from starved cells, cultures were washed and kept for 24h in suspension in PBS buffer before RNA extraction. In addition, total RNA was extracted from Mtb^ΔTA^ cultures carrying plasmid pGMCS-TetR-P1 (empty vector) or pGMCS-TetR-P1-Rv1989c, 6 or 24 h post-induction with ATc. RNA was prepared using the RNeasy kit (QIAGEN) following manufacturer's instructions with slight modifications ([@bib36]). RNA samples were treated for 30 min with 2U of Turbo DNase (Turbo DNA *free* kit, Ambion). The amount and purity of RNA were quantified using a NanoDrop ND-1000 apparatus (ThermoFischer Scientific) by measuring absorbance at 260/280 nm. Double-stranded cDNA was reverse-transcribed using the superscript III Reverse Transcriptase kit (Invitrogen), according to the manufacturer's protocol. For real-time qPCR, specific primers were designed and PCR reactions were performed using SYBR Green Premix Ex Taq (Ozyme), according to the manufacturer's protocol. All real-time qPCR reactions were carried out using a 7500 Real-Time PCR System and data were analyzed using the 7500 Software version 2.3 (Applied Biosystems). PCR array data were calculated by the comparative cycle threshold method, normalized with the *rpoB* housekeeping gene, and expressed as mean fold change in experimental samples relative to levels in Mtb WT grown in 7H9 ADC tween medium.

### Protein Expression and Purification {#sec3.4.7}

For expression of the intact MbcT-MbcA complex, pMyNT-MbcTA plasmid DNA was electroporated into *M. smegmatis* mc^2^155 groEL1ΔC ([@bib42]) and cultured in Middlebrook 7H9 medium, supplemented with 0.2% glucose, 0.2% glycerol and 0.05% Tween 80. Protein expression was induced with 2% (v/v) acetamide at an OD~600~ of 1.5. Cells were pelleted by centrifugation after xh incubation and resuspended in lysis buffer C (30 mM Tris (pH 8.0), 100 mM NaCl, 10 mM imidazole, 10% (w/v) glycerol) containing 1/100 protease inhibitor mix HP, 0.01% deoxyribonuclease I (Sigma-Aldrich) and disrupted using an Emulsiflex C3 high-pressure homogenizer (Avestin) by performing 5 cycles of ∼20,000 psi at 4°C. The cell suspension was centrifuged at 43,000 x g for 45 min at 4°C to pellet cell debris. MbcTA was purified from clarified lysate using a 5 mL HisTrap HP column. Following cleavage of the His~6~-tag with TEV protease, protein was concentrated and injected onto a Superdex 200 16/60 SEC column (GE Healthcare) pre-equilibrated in SEC buffer (30 mM Tris-HCl pH 8.0, 200 mM NaCl, 10% (w/v) glycerol) for removal of aggregated protein. Fractions containing MbcTA were pooled and concentrated to 12 mg ml^−1^. Samples were immediately used for crystallization or aliquoted and stored at −80°C. Proteins were routinely concentrated using Spin-X UF concentrators (Corning).

For expression of the MbcT-MbcA^Δ112−113^ complex, pnEK-MbcT and pnEA-His-MbcA^Δ112−113^ were co-transformed to *E. coli* BL21(DE3) CodonPlus-RIL. Protein expression was induced with 0.5 mM isopropyl-β-D-thiogalactopyranoside (IPTG) at an OD~600~ of 0.7. After xh incubation at xC, cells were pelleted by centrifugation and resuspended in lysis buffer A (30 mM Tris-HCl pH 8.0, 50 mM NaCl, 10 mM imidazole and 10% (w/v) glycerol) containing 1/100 protease inhibitor mix HP (Serva), 0.01% deoxyribonuclease I (Sigma-Aldrich). Cell disruption was achieved using an Emulsiflex C3 high pressure homogenizer (Avestin) by performing three cycles of ∼15,000 psi at 4°C. The cell suspension was centrifuged at 43,000 x g for 20 min at 4**°**C to pellet cell debris. MbcTA-containing lysate was loaded onto a 5 mL HisTrap HP (GE Healthcare) to bind the complex, followed by a salt wash with a linear gradient up to 2M NaCl. This salt wash resulted in MbcT-MbcA^Δ112−113^ dissociation and subsequent elution of MbcT. Fractions containing MbcT were buffer-exchanged to low salt buffer (30 mM Tris-HCl pH 8.0, 20 mM NaCl and 10% (w/v) glycerol), loaded onto a Mono Q 5/50 anion exchange chromatography column (QIAGEN), further concentrated and injected into a Superdex 75 16/60 size-exclusion chromatography (SEC) column (GE Healthcare) pre-equilibrated in SEC buffer for removal of aggregated protein.

MbcT R27E was produced as described for MbcT-MbcA^Δ112−113^ with following modifications. MbcT R27E-containing lysate in lysis buffer B (30 mM Tris-HCl pH 8.0, 200 mM NaCl, 10 mM imidazole, 10% (w/v) glycerol) was injected onto a 1 mL HisTrap HP column (GE Healthcare) and eluted using a linear gradient up to 300 mM imidazole. Following cleavage of the His~6~-tag with thrombin protease, the concentrated protein sample was injected onto a Superdex 75 16/60 SEC column pre-equilibrated in SEC buffer for removal of aggregated protein. Raw gel images are available on Mendeley Data (<https://doi.org/10.17632/y6ynjm5sf3.1>).

### Crystallography {#sec3.4.8}

Initial crystallization conditions for the MbcTA complex (12 mg ml^−1^) were identified using the Morpheus screen (Molecular Dimensions) and the PEGs suite (QIAGEN). Optimized rod-like crystals were obtained by the vapor diffusion method in 0.2 M ammonium sulfate, 0.1 M tri-sodium citrate pH 5.6 and 25% PEG 4000. Prior to data collection, crystals were transferred to a solution containing cryoprotectant that was optimized to a ratio of 2:2:1 of SEC buffer, precipitant, and glycerol, respectively, and mounted in a CryoLoop (Hampton).

All diffraction data were collected at EMBL beamline P13 ([@bib7]) at the PETRA III storage ring (DESY, Hamburg, Germany) using a low-energy set up with a Helium-cone covering the PILATUS 6M pixel-array detector (DECTRIS Ltd., Baden, Switzerland) running with custom low-energy calibration tables. Data for Sulfur Single-wavelength Anomalous Dispersion (S-SAD) phasing were collected with an X-ray beam of 70 μm in diameter at an energy of 5.0 keV (λ = 2.48 Å) on three different positions of a rod-shaped crystal with approximate dimensions of 300 × 70 × 70 μm^3^. At each position, 3600 frames of 0.1° per 40 ms exposure time were collected.

High-resolution native data were collected at an energy of 12.7 keV (λ = 0.976 Å) on a crystal with approximate dimensions of 500 × 100 × 100 μm^3^ with a beam of 100 μm in diameter employing a helical scan between two centring points ca. 400 μm apart. 1800 frames of 0.1° per 40 ms were recorded. Data were integrated with XDS and further processed with XSCALE ([@bib29]) and POINTLESS and AIMLESS from the CCP4 suite of programs ([@bib15], [@bib76]).

The crystal structure was solved using the SHELX suite ([@bib56]) of programs via the HKL2MAP user interface ([@bib46]). Unmerged data collected at low and high energy were supplied to SHELXC as SAD and NATIVE datasets respectively. For substructure solution, the anomalous differences determined by SHELXC were truncated at 3.0 Å. In 100 trials, 16 anomalous sites with occupancies higher than 0.6 were identified by SHELXD with a CFOM of 58.8. Phases calculated based on the substructure, after ten alternating cycles of density modification (assuming a solvent content of 44%) and main-chain auto-building as implemented in SHELXE resulted in 550 residues being placed into the experimentally phased electron density with correlation coefficient between the structure factors calculated for the partial structure and the experimental data of 46.7%.

Using the phases obtained from SHELXE, ARP/wARP ([@bib48]) was used to automatically build a first model consisting of 578 residues with R~work~- and R~free~-values of 0.30 and 0.25, respectively. The starting model was manually rebuilt with Coot ([@bib14]) and refined by iterative cycles using REFMAC ([@bib69]), PHENIX ([@bib1]), and the PDB_REDO web server ([@bib28]) using translation, liberation, and screw-rotation (TLS) groups as identified by the TLSMD server ([@bib44]). The quality of the final model was assessed using *Coot* ([@bib14]), the wwPDB validation server ([@bib19]) and the Molprobity server ([@bib6]). Structural figures were generated using PyMol (Schrödinger). Data statistics are presented in [Table 1](#tbl1){ref-type="table"}.

### Size Exclusion Chromatography Right-Angle Light Scattering {#sec3.4.9}

Protein mass measurements were performed on an Agilent HPLC system connected to a Viscotek 305 tri-detector (Malvern) to monitor static light scattering, refractive index, and UV absorbance. 100 μL sample was loaded onto a Superdex 200 HR 10/300 GL column (GE Healthcare) equilibrated in Size Exclusion Chromatography (SEC) buffer at a flow rate of 0.3 mL min^−1^. Data were recorded and processed using OmniSEC software (Agilent).

### Small Angle X-ray Scattering {#sec3.4.10}

Small angle X-ray scattering **(**SAXS) data were collected at EMBL beamline P12 at the PETRA III storage ring (DESY, Hamburg, Germany) ([@bib4]) using a 2M Pilatus pixel detector (DECTRIS) detector, a distance of 3.1 m and a wavelength of 1.24 Å ([Table 2](#tbl2){ref-type="table"}). MbcTA was measured at several protein concentrations in a range between ∼0.6 to ∼7.1 mg ml^−1^. Analysis of the scattering data was performed using the programs from the ATSAS 2.7 package ([@bib49]). The data obtained at the lowest and highest concentration were used for further analysis of MbcTA. The forward scattering I(0) and the radius of gyration R~g~ were calculated from the Guinier approximation calculated using PRIMUS GNOM ([@bib62]) was used to evaluate the pair distribution function, *P(r)*, and to calculate the maximum particle dimension (D~max~). *Ab initio* models for MbcTA were generated with DAMMIN ([@bib63]) utilizing a relaxed disconnectivity criterion without symmetry restrictions. Validation, resolution estimation and averaging for the final model building were performed with SASRES ([@bib68]) and DAMAVER ([@bib72]). Theoretical scattering curves were calculated using CRYSOL ([@bib64]). SUPCOMB ([@bib33]) was used for superimposition of the calculated *ab initio* model with the atomic structure. Data statistics are presented in [Table 2](#tbl2){ref-type="table"}.

### Circular Dichroism Spectroscopy {#sec3.4.11}

Samples were diluted to ∼0.1 mg ml^−1^ in buffer containing 250mM NaF and 10mM sodium phosphate (pH 7.5). Circular dichroism (CD) spectra were recorded between 190 and 320 nm at 10°C in a 1 mm QS quartz cuvette on a Chirascan CD Spectrometer upgraded with an Active Nitrogen Management System (Applied Photophysics). Instrument settings were as follows: 1 nm bandwidth, 1 s response and 0.5 nm data pitch. For each dataset 5 spectra have been averaged and sample buffer subtracted as background. Data were recorded with the Pro-Data Chirascan software (version 4.5.1833).

### Isolation of genomic DNA and total RNA {#sec3.4.12}

For isolation of genomic DNA, *E. coli* DH5α cells were cultured in LB medium to an OD~600~ of 0.7, collected and washed with PBS buffer. Genomic DNA was obtained using the DNeasy Blood & Tissue kit (QIAGEN) according to the manufacturer's instructions for Gram-negative bacteria, including RNaseA digestion. For isolation of total RNA, *E. coli* DH5α cells were cultured in LB medium to an OD~600~ of 0.7, mixed with RNAprotect Bacteria Reagent (QIAGEN) by vortexing followed by incubation for 5 min. at room temperature. Cells were pelleted by centrifugation and RNA was extracted according to the RNeasy Protect Bacteria Mini Kit protocol (QIAGEN) with a minor modification, namely DNase digestion was performed on-column for 30 min at 37°C.

### ADP ribosylation assays {#sec3.4.13}

For production of cell lysates, *E. coli* strain DH5α was cultured to an OD~600~ of 0.7. Cells were pelleted, washed with phosphate buffered saline (PBS) and resuspended in 1x BugBuster lysis reagent (Merck Millipore) supplemented with 1 mM dithiothreitol, 1x complete EDTA-free protease inhibitor cocktail (Roche) and 0.01 mg ml^−1^ deoxyribonuclease I. After 15 min incubation at room temperature, cell lysate was clarified by centrifugation at 20000 g, 4°C for 10 min. The supernatant was desalted using PD10 columns (GE Healthcare) in Tris buffer (20mM; pH 7.5) and protein concentration was measured using the BCA protein assay kit (ThermoFischer Scientific) following the manufacturer's instructions. *M. smegmatis* mc^2^155 groEL1ΔC ([@bib42]) cells were cultured to an OD~600~ of 1.5 in Middlebrook 7H9 medium, supplemented with 0.2% glucose, 0.2% glycerol and 0.05% Tween-80. *M. smegmatis* cell lysate was prepared as described for *E. coli* DH5α cells, with the exception of the cell lysis step. To ensure complete cell lysis, cell pellets were additionally incubated in a sonication bath for 5 min. Reactions were performed in 10 μL reaction buffer (50 mM Tris (pH 7.4), 200 mM NaCl, 2 mM MgCl~2~ and 1 mM DTT) containing MbcT and ∼1 μg of protein lysate, ∼50 ng denatured dsDNA or ∼1 μg RNA and/or spiked with ^32^P-NAD^+^. The final concentration of MbcT was 1 or 10 μM, when mixed with nucleosides or lysates respectively. The reactions were incubated at 37°C for 1 h. Reactions with protein lysate were analyzed by SDS-PAGE, gels were dried and exposed to autoradiography films. Reactions with DNA and RNA or without substrate were analyzed by thin layer chromatography.

### Thin Layer Chromatography {#sec3.4.14}

2 μL of each ADP-ribosylation reaction was spotted on polyethyleneimine (PEI) cellulose plates (Merck Millipore), which were air-dried prior to development with 0.25 M LiCl and 0.25 M formic acid. After drying, plates were exposed to an image plate (Fujifilm) and analyzed using a Phosphor-Imager (Fujifilm). Raw images are available on Mendeley Data (<https://doi.org/10.17632/y6ynjm5sf3.1>).

### LC-MS {#sec3.4.15}

LC-MS analysis was carried out on an Agilent system consisting of a 1290 Infinity II HPLC coupled to a 6230 TOF mass spectrometer with a dual Agilent Jet Stream (AJS) electrospray ionization source in negative mode. Ionization conditions were as follows: Nebuliser pressure 35 psi; N~2~ drying gas temperature and flow 200°C and 8 l min^−1^; N~2~ sheath gas temperature and flow 300°C and 11 l min^−1^; and capillary, nozzle, fragmentor, and octupole RF voltages 3000, 2000, 400 and 750 V, respectively. Compounds were separated with a Waters XBridge Amide column (3.5 μm; 4.6 mm × 100 mm). Phase A was 5% acetonitrile, 20 mM ammonium hydroxide and 20 mM ammonium acetate. Phase B was 100% acetonitrile ([@bib78]). Compounds were eluted at a flow rate of 0.4 mL min^−1^ and a temperature of 40°C with a gradient of 85%--60% B in 5 min, 60% B for 11 min, 60%--2% B in 5 min and 2%--80% B in 5 min. Data were collected and analyzed with MassHunter B 07.00.

### HPLC {#sec3.4.16}

Reactions were analyzed on an Agilent 1260 Infinity HPLC system using an Agilent Poroshell 120 EC-C18 column (2.7 um 4.6 × 50 mm) and monitoring absorbance at 260 nm. Elution was achieved with an isocratic flow of 2 ml/min of 10 mM ammonium phosphate pH 5.5 with 2.5% acetonitrile ([@bib41]). Data were collected and analyzed with OpenLAB CDS ChemStation (Agilent).

### NMR spectroscopy {#sec3.4.17}

Spectra were acquired in a Bruker Avance III HD spectrometer operating at a ^1^H frequency of 700 MHz and equipped with a 5 mm ^1^H/^31^P/^13^C/^15^N resonance PFG cryogenic probe. Data were processed and analyzed with Topspin 3.5. 1D and COSY HMBC NMR spectra are available on Mendeley Data (<https://doi.org/10.17632/y6ynjm5sf3.1>).

### Enzyme kinetics {#sec3.4.18}

All kinetic reactions were performed in 96-well plates. MbcT (50 nM) was incubated with different concentrations of NAD^+^ sodium salt (Sigma-Aldrich) at 37°C and the reaction time was adjusted in order to assure measurement of the initial rate of the reaction. Reactions were carried out in a final volume of 140 μL in reaction buffer (50 mM sodium-phosphate buffer (pH 7.5), 50 mM NaCl). For each time point, 10 μL of the reaction mixture was added to 300 μL of 5M NaOH and incubated in the dark at room temperature for 50 min to allow for the production of the alkaline-generated fluorescent species of NAD^+^. Fluorescence was measured at 360/460 nm (excitation/emission filter set) using a TECAN microplate reader. The concentration of NAD^+^ in each sample was calculated from the relative fluorescence correlated to a standard curve of NAD^+^. Initial rates of the reaction were determined by the linear regression of the plot of NAD^+^ consumption versus time, assuming saturating conditions of inorganic phosphate. Each calculated initial rate was plotted versus the corresponding NAD^+^ concentration. Michaelis Menten kinetics were used to determine K~M~, V~max~ for MbcT under each condition. K~cat~ was determined from the fit of the plot of K~obs~ (initial rate divided by enzyme concentration) versus NAD^+^ concentration. All calculations were performed using GraphPad Prism software.

### Western blotting {#sec3.4.19}

pET28a(+)-MbcT constructs were transformed to *E. coli* BL21 (DE3) and cultured in LB at 37°C. Protein expression was induced with IPTG (0.5mM) at an OD~600~ of 0.7 and cells were harvested 1 h after induction by centrifugation. Cells were resuspended in 1x BugBuster lysis reagent (Merck Millipore) supplemented with 0.13 mg ml^−1^ protease-inhibitor-mix HP (SERVA Electrophoresis) and 0.01 mg ml^−1^ deoxyribonuclease I (Sigma-Aldrich) and incubated at RT for 15 min. Protein lysates were separated by SDS-PAGE, transferred to Immuno-Blot PVDF membrane (Bio-Rad) using a Trans-Blot Turbo (Bio-Rad) and blocked overnight using 5% solution of skimmed milk powder (Carl Roth). Membranes were probed with either Penta His HRP conjugate (QIAGEN) or anti-GroEL (*E. coli*) monoclonal antibody (clone 9A1/2) (Enzo Life Sciences) as the primary antibody. HRP-linked whole Mouse IgG Antibody (GE Healthcare) was used for detection of GroEL. Blots were developed using SuperSignal West Pico Maximum Sensitivity Substrate (ThermoFisher Scientific) and visualized using a ChemiDoc MP (Bio-Rad). Raw blot images are available on Mendeley Data (<https://doi.org/10.17632/y6ynjm5sf3.1>).

### Determination of NAD^+^ levels in bacterial cells {#sec3.4.20}

Mtb^ΔTA^ strains containing pGMCS-TetR-P1 (empty vector), pGMCS-TetR-P1-Rv1989c or pGMCS-TetR-P1-Rv1989cR27E plasmids were cultured in 7H9 medium (Difco) supplemented with 10% albumin-dextrose-catalase (ADC, Difco), 0.05% Tween-80 (Sigma-Aldrich) at 37°C to OD~600~ of 0.2 prior to induction of protein expression with 200 ng ml^−1^ of anhydrotetracycline (ATc). 500 μL of culture was removed 24 h post-induction. Cells were harvested by centrifugation and resuspended in PBS buffer at an OD~600~ of 0.5. 0.1 μm-diameter glass beads were added to the tubes and cells were lysed by four 60 s pulses at full speed in a bead-beater device. The samples were centrifuged for 1 min at 20,200xg and the lysates were sterilized by filtration. Filtrates were mixed with an equal volume of NAD/NADH-Glo Detection Reagent (Promega) and luciferin bioluminescence was measured after 30 min of incubation using a CLARIOstar plate reader (BMG LABTECH) and normalized to background (PBS-only) signal.

### Macrophage infections {#sec3.4.21}

Before infection, mycobacterial clumps were disaggregated after at least 20 passages through a 25G needle. Human monocyte-derived macrophages were infected with *M. tuberculosis* at a multiplicity of infection of 0.3 bacteria/macrophage in complete RMPI medium for 4 h at 37°C. Cells were then washed with RPMI and further incubated at 37°C for 5 days in RPMI supplemented with or without ATc (200 ng ml^−1^). Measurements of macrophage viability were performed by flow cytometry analysis of cells treated with Zombie Aqua Fixable Viability Kit (BioLegends) as recommended by the manufacturer. Briefly, infected macrophages were recovered from the glass coverslips by treatment with non-enzymatic cell dissociation solution (Sigma-Aldrich). Macrophage pellets were resuspended in 100 μL Zombie Aqua solution in PBS and stained 20 min at 4°C. Macrophages were then washed in PBS, fixed for 2 h at room temperature in 200 μL of PBS containing 4% paraformaldehyde (Polyscience) and analyzed by flow cytometry (LSRII, BD Biosciences).

### Mice infections {#sec3.4.22}

Six- to eight-week-old female mice (SCID or C57BL/6J, Charles River) were anesthetized in gas chambers containing 0.5% isoflurane. SCID mice were infected by intravenous injection of ∼10^5^ CFUs of Mtb. Groups of 10 mice were provided with drinking water supplemented (or not) with 5% sucrose and 1 mg ml^−1^ of doxycycline from 7 days onward before infection and during the whole course of the Mtb infection. Survival was followed during time. C57BL/6J mice were infected intranasally with ∼10^3^ CFUs of Mtb in 25 μL of DPBS (GIBCO). At day 21 post-infection, groups of eight mice were fed by daily gavage with either water, isoniazid (25 mg kg^−1^), doxycycline (1 mg kg^−1^) or both during 10 days. At day 31 post-infection, mice were sacrificed and lung homogenates were plated onto 7H11 agar plates for CFU scoring.

Quantification and Statistical Analysis {#sec3.5}
---------------------------------------

Comparison of survival curves of SCID mice was performed with Log-rank (Mantel-Cox) test in GraphPad Prism software. Significance of variation in CFUs in lungs of infected C57BL/6J mice was performed using unpaired Student's tests in GraphPad Prism software. No animals were excluded from statistical analysis. p values correlate with symbols as follows: ns = not significant, p \> 0.05, ^∗^ p ≤ 0.05, ^∗∗^ p ≤ 0.01, ^∗∗∗^ p ≤ 0.001, ^∗∗∗∗^ p ≤ 0.0001.

Data and Software Availability {#sec3.6}
------------------------------

All raw images as well as the 1D and COSY HMBC NMR spectra are deposited on Mendeley Data (<https://doi.org/10.17632/y6ynjm5sf3.1>). The accession number for the MbcT-MbcA crystal structure reported in this paper is PDB: [6FKG](pdb:6FKG){#interref220}. The accession number for the MbcT-MbcA SAXS data reported in this paper is SASBDB: SASDD33.
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